RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature.

@article{Temming2005RGDbasedSF,
  title={RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature.},
  author={Kai Temming and Raymond M. Schiffelers and Grietje Molema and Robbert Jan Kok},
  journal={Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy},
  year={2005},
  volume={8 6},
  pages={
          381-402
        }
}
  • K. Temming, R. Schiffelers, +1 author R. Kok
  • Published 1 December 2005
  • Biology, Medicine
  • Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
During the past decade, RGD-peptides have become a popular tool for the targeting of drugs and imaging agents to alphavbeta3-integrin expressing tumour vasculature. RGD-peptides have been introduced by recombinant means into therapeutic proteins and viruses. Chemical means have been applied to couple RGD-peptides and RGD-mimetics to liposomes, polymers, peptides, small molecule drugs and radiotracers. Some of these products show impressive results in preclinical animal models and a RGD targeted… Expand
RGD Peptide as a Targeting Moiety for Theranostic Purpose: An Update Study
In the current scenario, the utility of peptide as the targeting ligand has been increased for the efficient diagnosis and treatment of tumor cells. Blood vessels of tumor cells show some molecularExpand
RGD peptide-based non-viral gene delivery vectors targeting integrin αvβ3 for cancer therapy
TLDR
Four types of RGD peptide-based non-viral gene delivery vectors for cancer therapy, including RGD-based cationic polymers, lipids, peptides and hybrid systems, are summarised to highlight the enhanced therapeutic effects and specific targeting ability exhibited by these vector for cancer gene therapy both in vitro and in vivo. Expand
Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region.
TLDR
A novel N-methylated RGD peptide was designed and its capability in targeting integrin presenting cells was comprehensively assessed both in vitro and in vivo and the RGDf[N-methyl]C-liposome was found promising in targeting tumor vasculature as well as other cells inside the tumor. Expand
Evaluation of RGD-targeted albumin carriers for specific delivery of auristatin E to tumor blood vessels.
Induction of apoptosis in endothelial cells is considered an attractive strategy to therapeutically interfere with a solid tumor's blood supply. In the present paper, we constructed cytotoxicExpand
cRGD functionalised nanocarriers for targeted delivery of bioactives
TLDR
Primary emphasis has been given on the application of cRGD-anchored nanocarriers for targeted delivery of drugs, imaging agents, etc. for tumour therapy. Expand
Functionalization of small rigid platforms with cyclic RGD peptides for targeting tumors overexpressing αvβ3-integrins.
TLDR
The grafted radiosensitizing nanoparticles were intravenously injected into Nude mice bearing subcutaneous U87MG tumors and the signal observed by optical imaging was twice as high for SRP-cRGDfK compared to their negative analogue. Expand
RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis.
TLDR
This review aims to particularly highlight the position of RGD-based nanoparticles in cancer therapy and imaging and the binding of the RGD peptide to this integrin. Expand
Nanoparticulate targeted drug delivery using peptides and proteins
: Targeted drug delivery has been widely explored as a strategy to increase drug efficacy and decrease side effects by guiding drugs to a specific location of action. One of the alternatives toExpand
αvβ3 Integrin-Targeted Peptide/Peptidomimetic-Drug Conjugates: In-Depth Analysis of the Linker Technology.
TLDR
This review surveys this approach with a special focus on the different linkers employed and the reported biological activities in vitro and in vivo of αvβ3 integrin- targeted small molecule-drug conjugates (SMDCs). Expand
RGD-modified PEG-PAMAM-DOX conjugate: in vitro and in vivo targeting to both tumor neovascular endothelial cells and tumor cells.
TLDR
A number of synthetic cyclized arginine–glycine–aspartic acid sequences (RGDs) containing peptides, such as RGDyK, RGDfK,RGDfV, andRGDyV, have been identified to have high affi nity with integrin α v β 3, making them an ideal target for drug delivery purposes. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 261 REFERENCES
Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics.
TLDR
The synthesis and biological evaluation of the first glycosylated RGD-containing peptide (RGD-peptide) for the noninvasive imaging of alpha(v)beta3 expression demonstrates that the introduction of a sugar moiety improves the pharmakokinetic behavior of the peptide. Expand
Novel RGD lipopeptides for the targeting of liposomes to integrin-expressing endothelial and melanoma cells.
TLDR
In vivo experiments applying doxorubicin-loaded RGD10 liposomes in a C26 colon carcinoma mouse model demonstrated improved efficacy compared with free doxorbicin and untargeted Liposomes and several of the isolated peptides possessed four cysteine residues. Expand
Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation.
TLDR
Compared to the 125I-RGD analog, this PEGylated RGD peptide revealed faster blood clearance, lower kidney uptake, and prolonged tumor uptake without compromising the receptor targeting ability. Expand
Preparation and functional evaluation of RGD-modified proteins as alpha(v)beta(3) integrin directed therapeutics.
TLDR
The conjugation of RGD-peptides to a protein, resulting in products that can bind multivalently, is a powerful approach to increase the affinity of peptide ligands for alpha(v)beta(3)/alpha( v) beta(5) integrins. Expand
Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery.
TLDR
The results demonstrate the potential of tumor-targeted delivery of paclitaxel based on the specific recognition of cell adhesion molecule alpha(v)beta(3) integrin to reduce toxicity and enhance selective killing of cancer cells. Expand
Peptide-targeted PEG-liposomes in anti-angiogenic therapy.
TLDR
It is demonstrated that the coupling of cyclic RGD-peptides or ATWLPPR- peptides to the surface of PEG-liposomes results in binding of these liposomes to endothelial cells in vitro and subsequent studies with RGD -peptide targeted liposome in vivo also demonstrate specific binding to the tumor endothelium. Expand
Targeting of RGD‐modified proteins to tumor vasculature: A pharmacokinetic and cellular distribution study
TLDR
Results indicate that RGD‐modified proteins are suitable carriers to deliver therapeutic agents into tumor or inflammation induced angiogenic endothelial cells. Expand
Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo.
TLDR
The results suggest that RGD-modified SSL may be a feasible intracellular targeting carrier for efficient delivery of chemotherapeutic agents into tumor cells. Expand
Endothelial cells internalize and degrade RGD-modified proteins developed for tumor vasculature targeting.
  • A. J. Schraa, R. Kok, +5 authors G. Molema
  • Biology, Medicine
  • Journal of controlled release : official journal of the Controlled Release Society
  • 2002
TLDR
This is the first study that shows direct evidence that primary endothelial cells are capable of internalizing RGD-containing macromolecular proteins and was shown to be internalized and degraded by HUVEC, a process that could be inhibited by lysosomal degradation inhibitors chloroquine and ammonium chloride. Expand
Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation.
TLDR
Solid-phase peptide synthesis of multimeric cyclo(-RGDfE-)-peptides is described, which offer the possibility of enhanced integrin targeting due to polyvalency effects, and an aminooxy group for versatile chemoselective oxime ligation. Expand
...
1
2
3
4
5
...